Skip to main
TRVI

TRVI Stock Forecast & Price Target

TRVI Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Trevi Therapeutics is poised to become a leader in the development and commercialization of Haduvio, an investigational therapy for chronic cough in a variety of indications. With a strong pipeline and promising clinical data, the company has the potential to capture a significant market share in the treatment of chronic cough. Additionally, the recent discontinuation of a competing therapy by GSK suggests that Haduvio has a strong chance of becoming a first-in-class and best-in-class therapy.

Bears say

Trevi Therapeutics is facing a bleak future as their drug Haduvio's strong IP may not be enough to protect them from generic versions due to its non-composition-of-matter protection. Despite outperforming in 2026 and providing guidance for a range of $2.40 to $2.80 for 2027 EPS, the share price is trading at 5.8x forward EPS, indicating a lack of confidence in the company's potential success. Additionally, while the CORAL study showed promising results, further trials will be needed to replicate them, raising concerns about the consistency of the drug's efficacy.

TRVI has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Trevi Therapeutics Inc (TRVI) Forecast

Analysts have given TRVI a Strong Buy based on their latest research and market trends.

According to 12 analysts, TRVI has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Trevi Therapeutics Inc (TRVI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.